At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo And NSAID Controlled Study To Evaluate The Efficacy And Safety Of Fasinumab In Patients With Pain Due To Osteoarthritis Of The Knee Or Hip
In Brief
A Phase 3 clinical trial evaluating Fasinumab, Diclofenac, and 2 other interventions for Osteoarthritis, Knee and Osteoarthritis, Hip. Completed, enrolled 1,650 participants across 71 sites.
Detailed Summary
The primary objective of the study is to evaluate the efficacy of fasinumab compared to placebo, when administered for up to 24 weeks in patients with pain due to osteoarthritis (OA) of the knee or hip. The secondary objectives of the study are: * To evaluate the efficacy of fasinumab compared to non-steroidal anti-inflammatory drugs (NSAID)s, when administered for up to 24 weeks in patients with pain due to OA of the knee or hip * To assess the safety and tolerability of fasinumab compared to placebo and compared to NSAIDs, when administered for up to 24 weeks in patients with pain due to OA of the knee or hip
Study Details
Timeline
Interventions
Solution for injection in pre-filled syringe
NSAID active comparator (capsule)
NSAID active comparator (capsule)
Fasinumab-matching placebo (solution for injection in pre-filled syringe); NSAID-matching placebo (capsule)